Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 229

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Towards precision oncology in advanced prostate cancer

Open access
Ku, Sheng-Yu, Gleave, Martin E., Beltran, Himisha · 2019 · Nature Reviews Urology

Abstract

Metastatic biopsy programmes combined with advances in genomic sequencing have provided new insights into the molecular landscape of castration-resistant prostate cancer (CRPC), identifying actionable targets, and emerging resistance mechanisms. The detection of DNA repair aberrations, such as mutation of BRCA2, could help select patients for poly(ADP-ribose) polymerase (PARP) inhibitor or platinum chemotherapy, and mismatch repair gene defects and microsatellite instability have been associated with responses to checkpoint inhibitor immunotherapy. Poor prognostic features, such as the presence of RB1 deletion, might help guide future therapeutic strategies. Our understanding of the molecular features of CRPC is now being translated into the clinic in the form of increased molecular testing for use of these agents and for clinical trial eligibility. Genomic testing offers opportunities for improving patient selection for systemic therapies and, ultimately, patient outcomes. However, challenges for precision oncology in advanced prostate cancer still remain, including the contribution of tumour heterogeneity, the timing and potential cooperation of multiple driver gene aberrations, and diverse resistant mechanisms. Defining the optimal use of molecular biomarkers in the clinic, including tissue-based and liquid biopsies, is a rapidly evolving field. A number of targetable molecular alterations and resistance mechanisms have been identified in metastatic castration-resistant prostate cancer (mCRPC). As our understanding of the genomic landscape of mCRPC increases, biomarker-driven clinical trials investigating targeted therapies will enable an increasingly personalized approach to its treatment. Studies investigating the genomic landscape of metastatic prostate cancer have identified targetable molecular alterations and emerging resistance mechanisms.Alterations in the androgen receptor (AR) gene are a key driver of castration resistance in prostate cancer; AR mutation, amplification and the V7 splice variant can be detected non-invasively in patients, and have been associated with resistance to AR pathway inhibitors.A subset of advanced prostate cancers harbour germline or somatic alterations involving DNA repair genes; homologous repair gene DNA repair defects have been associated with platinum chemotherapy and poly(ADP-ribose) polymerase (PARP) inhibitor sensitivity. Mismatch repair gene and CDK12 loss have been associated with responses to immunotherapy.Combined loss of tumour suppressors RB1 and TP53 has been associated with lineage plasticity and the development of non-AR driven therapy resistance, which is enriched in tumours with small-cell and/or neuroendocrine pathological features on metastatic biopsy and aggressive clinical features.Several biomarker-driven clinical trials are underway in patients with advanced prostate cancer that might ultimately lead to increasingly precise therapeutic strategies in patients. Studies investigating the genomic landscape of metastatic prostate cancer have identified targetable molecular alterations and emerging resistance mechanisms. Alterations in the androgen receptor (AR) gene are a key driver of castration resistance in prostate cancer; AR mutation, amplification and the V7 splice variant can be detected non-invasively in patients, and have been associated with resistance to AR pathway inhibitors. A subset of advanced prostate cancers harbour germline or somatic alterations involving DNA repair genes; homologous repair gene DNA repair defects have been associated with platinum chemotherapy and poly(ADP-ribose) polymerase (PARP) inhibitor sensitivity. Mismatch repair gene and CDK12 loss have been associated with responses to immunotherapy. Combined loss of tumour suppressors RB1 and TP53 has been associated with lineage plasticity and the development of non-AR driven therapy resistance, which is enriched in tumours with small-cell and/or neuroendocrine pathological features on metastatic biopsy and aggressive clinical features. Several biomarker-driven clinical trials are underway in patients with advanced prostate cancer that might ultimately lead to increasingly precise therapeutic strategies in patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41585-019-0237-8

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Cited by

See all 229

Metadata

Authors
Ku, S.-Y., Gleave, M. E., & Beltran, H.
Venue
Nature Reviews Urology
Published
2019-10-07
Volume
16
Issue
11
Pages
645-654
ISSN
  • 1759-4812 (ISSN-L)
  • 1759-4820
OpenAlex
W2979280650
Cited by
229
References
31
FWCI
6.87
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Towards precision oncology in advanced prostate cancer. https://app.cochat.ai/papers/10.1038/s41585-019-0237-8
The paper
Ku, S.-Y., Gleave, M. E., & Beltran, H. (2019). Towards precision oncology in advanced prostate cancer. Nature Reviews Urology. https://doi.org/10.1038/s41585-019-0237-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.